Monitoring chemokine concentrations in peripheral blood and changes in the ratio of CD4+ T and CD8+ T cells could indicate an improvement in the immune status of cancer patients, which may be useful for evaluating the efficacy of tumor treatment in the future. This evidence concerns the gene CD4 and neoplasm.